

# Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

## CD22 Antibody, anti-human, PE, REAfinity™

RRID:AB\_2802011

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-123-245, RRID:AB\_2802011

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2802011](http://antibodyregistry.org/AB_2802011)

**Proper Citation:** Miltenyi Biotec Cat# 130-123-245, RRID:AB\_2802011

**Target Antigen:** CD22

**Host Organism:** human

**Clonality:** monoclonal

**Comments:** Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-105-056. (RRID:AB\_2656358).

**Antibody Name:** CD22 Antibody, anti-human, PE, REAfinity™

**Description:** This monoclonal targets CD22

**Target Organism:** human

**Clone ID:** clone REA340

**Antibody ID:** AB\_2802011

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-123-245

**Record Creation Time:** 20250819T212535+0000

**Record Last Update:** 20250819T225525+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD22 Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD22 Antibody, anti-human, PE, REAfinity™.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.